CJC-1295 (No DAC) / Ipamorelin is a combination of two synthetic research peptides that have been widely investigated in laboratory settings for their interaction with growth hormone regulatory pathways. CJC-1295 (No DAC), also known as Modified GRF 1-29, has been studied for its interaction with growth hormone-releasing hormone (GHRH) receptors, while Ipamorelin has been investigated for its selective interaction with ghrelin (GHS-R1a) receptors. This product is supplied exclusively for controlled laboratory and research use and is intended only for qualified scientific investigation.

As part of Retro Wellness’ research compound range, CJC-1295 (No DAC) / Ipamorelin is presented with a focus on consistency, quality, and responsible sourcing. Each product is intended strictly for qualified research settings and should only be handled by individuals or organisations with the appropriate facilities, knowledge, and procedures.

Research involving CJC-1295 (No DAC) / Ipamorelin has explored its interaction with biological pathways associated with pulsatile growth hormone signalling, pituitary receptor activity, insulin-like growth factor-1 (IGF-1) regulation, and endocrine signalling mechanisms. Experimental studies have also examined the complementary actions of GHRH receptor agonism and ghrelin receptor activation within controlled laboratory models to better understand hormonal signalling and physiological regulation. Ongoing research continues to expand understanding of these mechanisms and their broader relevance within endocrine and molecular science.

This product is not a medicine, supplement, cosmetic, or food product. It is not intended for human or veterinary use, diagnosis, treatment, prevention, or consumption.